Previous 10 | Next 10 |
Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares PR Newswire DUBLIN , June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focuse...
Theravance Biopharma (TBPH) was down 10% to $15.39 post market while it announced an offering of its ordinary shares.The company also intends to grant the underwriters a 30-day option to buy up to an additional 15% of the shares sold in the offering.Theravance intends to use the net proc...
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares PR Newswire DUBLIN , June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on th...
Merger news and drug development moved some stocks in Monday's pre-market action. Raven (RAVN) and Rafael Holdings (RFL) advanced on merger deals. Meanwhile, MediciNova (MNOV) and Theravance Bio (TBPH) moved in opposite directions on the release of new clinical trial data.The return of travel...
Theravance Biopharma (TBPH) drops 6.4% premarket after announcing top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care for hospitalized patients with confirmed COVID-19 associated acute lung injury and...
Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 - Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: number of Respiratory Failure-Free Day...
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March. Aggressive selling on up and down days, with clear relative price weaknes...
The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...
Seth Klarman’s 13F portfolio value increased from $10.84B to $12.56B this quarter. Baupost Group increased Alphabet and Intel while reducing Fox Corp and dropping ViacomCBS. They also built small stakes in several SPACs. The portfolio continues to be heavily concentrated wi...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Theravance Biopharma, Inc. 2021 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...